These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22689319)

  • 1. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation.
    Cohen S; Tacke CE; Straver B; Meijer N; Kuipers IM; Kuijpers TW
    Ann Rheum Dis; 2012 Dec; 71(12):2059-61. PubMed ID: 22689319
    [No Abstract]   [Full Text] [Related]  

  • 2. Extracorporeal membrane oxygenation for Kawasaki disease: two case reports and the Extracorporeal Life Support Organization experience 1999-2015.
    Best D; Millar J; Kornilov I; Sinelnikov Y; Chiletti R; Rycus P; Butt W
    Perfusion; 2017 Oct; 32(7):609-612. PubMed ID: 28985704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra.
    Blonz G; Lacroix S; Benbrik N; Warin-Fresse K; Masseau A; Trewick D; Hamidou M; Stephan JL; Néel A
    J Clin Rheumatol; 2020 Mar; 26(2):e42-e43. PubMed ID: 32073531
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    Lind-Holst M; Hartling UB; Christensen AE
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31383678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.
    Burns JC; Koné-Paut I; Kuijpers T; Shimizu C; Tremoulet A; Arditi M
    Arthritis Rheumatol; 2017 Feb; 69(2):268-276. PubMed ID: 27792871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant and fusiform aneurysms of coronary arteries following early and adequate treatment of suspected Kawasaki disease.
    Oechslin EC; Arbenz U; Mayer K
    Heart; 2004 Dec; 90(12):1437. PubMed ID: 15547023
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anakinra in the treatment of Kawasaki disease: mechanisms, efficacy and safety].
    Tong T; Wang YJ; Gong FQ
    Zhonghua Er Ke Za Zhi; 2021 Nov; 59(11):997-1000. PubMed ID: 34711041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe dyshidrotic eczema after intravenous immunoglobulin therapy for Kawasaki syndrome.
    Shiraishi T; Yamamoto T
    Pediatr Dermatol; 2013; 30(3):e30-1. PubMed ID: 22304420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease. Involution of giant coronary aneurysms after prolonged anti-inflammatory treatment.
    Atik E; Foronda A; Bustamante LN
    Arq Bras Cardiol; 2003 Sep; 81(3):265-72. PubMed ID: 14649251
    [No Abstract]   [Full Text] [Related]  

  • 10. Kawasaki disease recurrence with cardiac tamponade.
    Ulger Z; Levent E; Ozdemir R; Ozyürek AR
    Anadolu Kardiyol Derg; 2005 Sep; 5(3):234-6. PubMed ID: 16140659
    [No Abstract]   [Full Text] [Related]  

  • 11. Kawasaki disease and scald injuries: a possible association.
    Wong D; Nutting A; Yeung RS; McCrindle BW
    Can J Cardiol; 2004 Sep; 20(11):1147-9. PubMed ID: 15457311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunopathogenesis and management of Kawasaki syndrome.
    Leung DY; Schlievert PM; Meissner HC
    Arthritis Rheum; 1998 Sep; 41(9):1538-47. PubMed ID: 9751085
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome.
    Baer AZ; Rubin LG; Shapiro CA; Sood SK; Rajan S; Shapir Y; Romano A; Bierman FZ
    Arch Pediatr Adolesc Med; 2006 Jul; 160(7):686-90. PubMed ID: 16818833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy.
    Ichihashi K; Shiraishi H; Momoi M
    Cardiol Young; 2009 Jun; 19(3):224-7. PubMed ID: 19272202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe neonatal Kawasaki disease].
    Moruno Tirado A; Grueso Montero J; Macías Díaz C; Zamarriego Zubizarreta C; Santos de Soto J
    An Pediatr (Barc); 2007 Oct; 67(4):401-2. PubMed ID: 17949653
    [No Abstract]   [Full Text] [Related]  

  • 16. Kawasaki Disease: is atypical more common than typical.
    Mishra K; Choudhury J
    Indian Pediatr; 2006 May; 43(5):453-4. PubMed ID: 16735773
    [No Abstract]   [Full Text] [Related]  

  • 17. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.
    Ryan JG; de Koning HD; Beck LA; Booty MG; Kastner DL; Simon A
    J Allergy Clin Immunol; 2008 Jan; 121(1):260-2. PubMed ID: 17936890
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiac manifestation of mucocutaneous lymph node syndrome (Kawasaki disease).
    Ren X; Banker R
    J Am Coll Cardiol; 2009 Jun; 54(1):89. PubMed ID: 19555847
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome.
    Kuemmerle-Deschner JB; Tyrrell PN; Koetter I; Wittkowski H; Bialkowski A; Tzaribachev N; Lohse P; Koitchev A; Deuter C; Foell D; Benseler SM
    Arthritis Rheum; 2011 Mar; 63(3):840-9. PubMed ID: 21360513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kawasaki disease: part I. Diagnosis, clinical features, and pathogenesis.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):501.e1-11; quiz 511-2. PubMed ID: 24034379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.